Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02852837
Recruitment Status : Active, not recruiting
First Posted : August 2, 2016
Last Update Posted : July 19, 2019
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : January 13, 2020
Estimated Study Completion Date : January 13, 2020